The SVR12 rates were comparable with regard to age at a cut-off value of 55 years, sex, prior IFN exposure, HBV or HIV coinfection, prior history of HCC, scheduled 12 or 24 weeks of treatment, use of RBV, BMI at a cut-off value of 25 kg/m2, ALT quotient at a cut-off of 2, eGFR at a cut-off value of 60 mL/min/1.73 m2, baseline HCV viral load at a cut-off value of 6,000,000 IU/mL, HCV genotype, cirrhosis and week 4 viral decline in patients receiving SOF-based regimens. The gene discussed is GPT; the disease is hepatocellular carcinoma.